Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis Abstract Background and aims of the study: Atopic dermatitis is a chronic inflammatory skin disorder that often involves some ophthalmic features. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that is associated with the generation of cell-mediated immune responses. Although serum MIF levels may be elevated in severe atopic dermatitis, the quantity of MIF in regional ocular fluid remains unknown. We measured MIF levels in tears (lacrimal fluid) of patients with atopic dermatitis. Patients and methods: Tear samples were collected from 16 patients with atopic dermatitis, 10 patients with allergic conjunctivitis, and 15 healthy control subjects. The clinical severity of atopic dermatitis was evaluated according to the Scoring Atopic Dermatitis (SCORAD) index. The index was calculated by summing the following scores: extent criteria, intensity criteria, and subjective symptoms. Macrophage migration inhibitory factor levels were determined by a human MIF enzyme-linked immunosorbent assay. All comparisons were twotailed, and P values <0.01 were considered as statistically significant. Results: The mean MIF concentration in lacrimal fluid collected from healthy control subjects was 0.69± 0.2 ng/ml. The mean tear MIF levels were 17.87± 6.3 ng/ml in moderate-to-severe atopic dermatitis (SCORAD≥ 15, P=0.002), 0.93±0.08 ng/ml in mild atopic dermatitis (SCORAD< 15), and 2.76± 0.86 ng/ml in allergic conjunctivitis (P=0.008). Conclusions: A proinflammatory cytokine MIF level was elevated in tears as well as serum in cases of severe atopic dermatitis. These results suggest that MIF may play an important role in the induction or enhancement of ophthalmic features related to severe atopic dermatitis.
Introduction
Macrophage migration inhibitory factor (MIF) was first discovered in the late 1960s; it is therefore believed to be the first recognized lymphokine [6] . Since MIF was discovered as merely a part of the phenomenon of inhibiting migration of macrophages in the pre-molecular biology era, many scientists doubted its importance in the immune response. Investigations in the 1990s aimed at identifying novel systemic mediators that could regulate host inflammatory responses led to the identification of murine MIF as a product secreted by the anterior pituitary gland [2] . Upon stimulation, T cells release MIF, and MIF activity was first described as a product of cognate T-cell supernatants [15] . Macrophages have also been identified as an important source of MIF and are known to express MIF both constitutively and upon stimulation [15] . Macrophage migration inhibitory factor is considered to act by both paracrine and autocrine stimulatory pathways to augment the activation of these cells [15] . As reported previously, MIF is essential for T-cell activation and possibly contributes to maintaining Th1/Th2 imbalance [1] . Increased MIF expression has been reported in lesions from many immune/inflammatory diseases, including psoriasis, glomerulonephritis, transplant rejection, neuroBehçet's disease, asthma, adult respiratory distress syndrome, and inflammatory eye diseases [3, 4, 7, 11-13, 16, 17, 20, 22, 24] .
Atopic dermatitis (AD) frequently involves some ophthalmic features: blepharitis, chronic keratoconjunctivitis, keratoconus, early-onset cataract, and rarely, retinal detachment [9] . AD is a chronic inflammatory skin disorder and many reports have documented its pathogenesis in relation to genetic and immunological abnormalities as well as environmental factors [10] . Although abnormal populations of Th1 and Th2 subsets of helper T cells (Th1/ Th2 imbalance) have been identified as a cause of the pathogenesis of AD [8, 13, 25] , a decrease in delayed-type hypersensitivity (DTH) is considered to involve more than Th1/Th2 imbalance in AD [5] . MIF is essential for T-cell activation and possibly contributes to maintaining Th1/Th2 imbalance as described above [1] . Also, a prominent increase in systemic MIF levels was detected in patients with severe AD, and the levels decreased when the clinical symptoms improved following treatment with corticosteroid ointment [18, 19] . We hypothesized that a high concentration of MIF could exist in the regional fluid of the eye as well as in serum in cases of severe atopic dermatitis. Because the Scoring Atopic Dermatitis (SCORAD) index, which is determined on the basis of several criteria related to lesion spread and intensity as well as on subjective signs, is commonly used to evaluate AD [21] , AD patients were classified into two groups, as moderate-to-severe or mild AD, according to SCORAD index in the present study. We measured the MIF levels in tears (lacrimal fluid) of patients with AD and compared them to those of patients with allergic conjunctivitis (AC) and healthy people.
Materials and methods

Patients
We studied 16 patients with AD and 9 subjects with AC who visited the Departments of Dermatology and Ophthalmology, Hokkaido University Hospital, Sapporo, Japan. Atopic dermatitis is a common inflammatory disorder characterized by a chronic and relapsing course. In order to evaluate the severity of the disease as objectively as possible, the European Task Force on Atopic Dermatitis developed a method allowing consistent assessment by means of a severity index, called the Scoring Atopic Dermatitis (SCORAD) index [21] . The index should be calculated as a sum of the following scores: (1) extent criteria (involved surface area), (2) intensity criteria (erythema, edema/papulation, oozing/crusting, excoriation, and lichenification), and (3) subjective symptoms (pruritus and insomnia) [21] . We classified cases of AD in this study as "moderate-to-severe" (SCORAD≥15) or "mild" (SCORAD<15) according to the SCORAD index. Each patient with moderate-to-severe AD had atopic manifestations on the facial skin. Allergic conjunctivitis (AC) was diagnosed by slit lamp examination according to the guidelines of diagnosis and treatment of conjunctivitis, reported elsewhere [23] . Although we collected tear samples out of pollen season (December, January, and February), five of ten AC patients stated that they had sensitivity to grass or birch pollen. Most of the AC patients were considered to be in the chronic phase of AC, and their conjunctival signs and symptoms were mild. Tear samples were collected from 9 patients with severe AD (mean age, 26.1 years; age range, 18-37 years), 7 patients with mild AD (mean age, 29.0 years; age range, 16-44 years), 10 patients with AC (mean age, 32.6 years; age range, 22-44 years), and 15 healthy volunteers (mean age, 34.6 years; age range, 23-45 years). All subjects were Japanese, and healthy volunteers with no history of AD were recruited from our colleagues as controls. Dermatologists and ophthalmologists also verified no manifestations of AD and AC in controls when their tear/serum samples were collected. Informed consent was obtained from every patient and control subject.
Collection of tears and sera
All of the experiments in this study followed the tenets of the Declaration of Helsinki. After informed consent was obtained, tear samples were collected from all subjects. To obtain unstimulated basal lacrimal fluid, the tear samples (10 μl) were collected with microcapillary tubes for microhematocrit (75 mm length, Funakoshi, Tokyo) at the lateral canthus of patients in the supine position without any anesthesia. After obtaining informed consent, serum samples were collected from two of the severe AD patients whose tear MIF levels were quite high (>27.2 ng/ml), exceeding one standard deviation (SD) from the group's median value. Also, two subjects were chosen randomly from the patients with mild AD and healthy controls to measure their serum MIF levels.
Tear samples were centrifuged immediately at 4°C to remove cells and transferred into new tubes. Tear and serum samples were stored at −80°C until further examination.
Measurement of MIF
Macrophage migration inhibitory factor levels were determined by a human MIF enzyme-linked immunosorbent assay (ELISA) (CosmoBio, Tokyo, Japan) as described previously [18] . The kit contains all reagents necessary for performing the assay. Statistical analysis was performed using the Mann-Whitney U test.
Results
The mean MIF level in lacrimal fluid collected from healthy control subjects was 0.69±0.2 ng/ml. The mean tear MIF levels were 17.87±6.3 ng/ml in cases of moderateto-severe AD (SCORAD≥15), 0.93±0.08 ng/ml in cases of mild AD (SCORAD<15), and 2.76±0.86 ng/ml in cases of allergic conjunctivitis (AC). Tear MIF levels were significantly elevated in patients with moderate-to-severe AD compared to normal controls (P=0.002, Table 1 ). The tear MIF levels of patients with AC were also higher than those of healthy subjects (P=0.008, Table 1 ). We did not, however, detect any significant difference in tear MIF levels between patients with mild AD (SCORAD<15) and healthy control subjects (P=0.07, Table 1 ).
We then focused on two cases of severe AD in which the tear MIF levels were higher than 27.2 ng/ml, i.e., more than one standard deviation (SD) from the group's median value. Both had the severest skin manifestations of atopic dermatitis in this study when their tears were collected. After informed consent was obtained from these patients, serum samples were drawn and the serum MIF levels were measured. As shown in Table 2 , their serum MIF levels were approximately equivalent to those in the lacrimal fluid of patients with severe AD. In contrast, although the serum MIF levels in cases of mild AD were still elevated compared to those of healthy controls, their MIF concentrations in tears were no higher than those of healthy controls (Table 2) .
Discussion
In the present study, we detected high levels of MIF in the lacrimal fluid of patients with severe AD. We previously reported an increase in serum MIF levels in patients with AD [18] . Although AD frequently involves some ophthalmic features (blepharitis, chronic keratoconjunctivitis, keratoconus, early-onset cataract, and retinal detachment), how MIF behaves in the ocular fluid of patients with AD remained unknown. We wished to determine how tear MIF levels of patients with severe AD compared with AC and healthy subjects.
MIF is expressed and secreted in many tissues: in the brain, eye (lens, corneal epithelial cells, iris, ciliary body, and retina), ear, immune cells (thymus, spleen, lymph nodes, blood, and bone marrow, by monocytes, macrophages, T cells, B cells, dendritic cells, eosinophils, basophils, neutrophils, and mast cells), lungs, breast, endocrine systems (pituitary gland, adrenal cortex, and pacreas), liver, testis, prostate, ovaries, gastrointestinal tract, kidney, fat tissue, skin (by keratinocytes, sebaceous glands, hair follicles, endothelial cells and fibroblasts), bone, and joints [4] . This study demonstrated that tear MIF concentration is significantly higher in patients with severe AD than in controls. Patients with AC also showed significantly higher levels of MIF than healthy controls; however, there were vast differences between the averages of AD and AC groups.
Since MIF levels in tears were elevated for both diseases involving the immune system, one possible source of tear MIF is the lymphocytes in conjunctival follicles. Another possible cause of the elevation of tear MIF levels in the eyes may be the lacrimal gland, but no study has been performed to determine if the lacrimal gland expresses or secretes MIF or not. A third possible source may be peripheral blood mononuclear cells (PBMCs) [14] . As previously reported, a substantial increase in systemic MIF levels was detected in patients with severe AD, and the levels decreased when the skin symptoms improved following treatment with corticosteroid ointment [18] . Furthermore, the elevated serum MIF was due to secretion from systemic PBMC [18, 19] . We found two patients with severe AD who showed extremely high levels (in excess of 30 ng/ml) of MIF in this study. To examine how blood PBMC contributes to MIF levels in lacrimal fluid, we collected serum samples from AD patients as well as tears. Because a very high serum MIF concentration was detected in both of these patients (Table 2 ) and the space of the oculi is limited, some proportion of MIF in tears may be attributable to a systemic increase in MIF. The secretion of MIF from PBMCs might contribute to the elevation of tear MIF levels more than regional inflammatory cells of the eyes in patients with severe AD. Since we did not collect blood samples from AC subjects, it is still unclear how much blood PBMC contributes to tear MIF levels in cases of AC. In the present study, AC patients did not have This is the first report that MIF concentrations in tears are elevated in cases of severe AD in humans. In conclusion, MIF in regional ocular fluid may be involved in the induction or enhancement of ophthalmic features caused by severe AD.
